

Table S1. Definitions used to identify residents with active coronary artery disease, stroke/transient ischemic attack, and/or diabetes.

	Diagnosis Code Algorithm		MDS indicators
<i>Conditions</i>	<i>Number/type of claims</i>	<i>ICD-9/CPT4/HCPCS Codes</i>	
Coronary Artery Disease	At least 1 of the following claim/encounter type in the 2 years prior to admission: <ul style="list-style-type: none"> - Medicare hospital inpatient - Medicare skilled nursing facility - Medicare home health - Medicare hospital outpatient - Medicare carrier - VA inpatient (including fee basis) - VA outpatient (including fee basis) 	DX 410.00, 410.01, 410.02, 410.10, 410.11, 410.12, 410.20, 410.21, 410.22, 410.30, 410.31, 410.32, 410.40, 410.41, 410.42, 410.50, 410.51, 410.52, 410.60, 410.61, 410.62, 410.70, 410.71, 410.72, 410.80, 410.81, 410.82, 410.90, 410.91, 410.92, 411.0, 411.1, 411.81, 411.89, 412, 413.0, 413.1, 413.9, 414.00, 414.01, 414.02, 414.03, 414.04, 414.05, 414.06, 414.07, 414.12, 414.2, 414.3, 414.4, 414.8, 414.9 (any DX on the claim)	V2.0: I1d V3.0: I0400
Stroke/TIA	At least 1 of the following during the 1 year prior to admission date: <ul style="list-style-type: none"> - Medicare inpatient - VA inpatient (including fee basis) <p style="text-align: center;">OR</p> At least 2 of the following (on different dates, if in same system) during the 1 year prior to admission date: <ul style="list-style-type: none"> - Medicare outpatient - Medicare carrier - VA outpatient (including fee basis) 	DX 430, 431, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.00, 434.01, 434.10, 434.11, 434.90, 434.91, 435.0, 435.1, 435.3, 435.8, 435.9, 436, 997.02 (any DX on the claim)	V2.0: I1t or I1bb V3.0: I4500
Diabetes	At least 1 of the following during the 2 years prior to admission date: <ul style="list-style-type: none"> - Medicare inpatient - Medicare skilled nursing facility - Medicare home health - VA inpatient (including fee basis) <p style="text-align: center;">OR</p> At least 2 of the following (on different dates, if in same system) during the 2 years prior to admission date: <ul style="list-style-type: none"> - Medicare outpatient - Medicare carrier - VA outpatient (including fee basis) - 	DX 249.00, 249.01, 249.10, 249.11, 249.20, 249.21, 249.30, 249.31, 249.40, 249.41, 249.50, 249.51, 249.60, 249.61, 249.70, 249.71, 249.80, 249.81, 249.90, 249.91, 250.00, 250.01, 250.02, 250.03, 250.10, 250.11, 250.12, 250.13, 250.20, 250.21, 250.22, 250.23, 250.30, 250.31, 250.32, 250.33, 250.40, 250.41, 250.42, 250.43, 250.50, 250.51, 250.52, 250.53, 250.60, 250.61, 250.62, 250.63, 250.70, 250.71, 250.72, 250.73, 250.80, 250.81, 250.82, 250.83, 250.90, 250.91, 250.92, 250.93, 357.2, 362.01, 362.02, 362.03, 362.04, 362.05, 362.06, 366.41 (any DX on the claim)	V2.0: I1a V3.0: I2900

Table S-2. VA facility complexity categorization scheme.

Complexity Level	Description
1a	Largest levels of volume, patient risk, teaching, research, and number and breadth of physician specialists; level 5 Intensive Care Units (ICUs).
1b	Very large levels of patient volume, risk, teaching and research; level 4 and 5 ICUs.
1c	Large levels of volume, risk, teaching, and research; level 4 ICUs.
2	Medium patient risk, teaching, and research; level 3 and 4 ICUs.
3	Lowest levels of volume and patient risk; little or no teaching and research; lowest number of physician specialists; level 1 and 2 ICUs.

Table S-3. Multivariable sub-distribution hazard ratios from Fine and Gray competing risk models assessing factors associated with statin discontinuation, overall and by end-of-life designation/hospice use at admission.

	Full Sample (n=13,110)	End-of-Life Designation/ Hospice (n=2,374)	No End-of-Life Designation/ Hospice (n=10,736)
	SDHR (95% CI)	SDHR (95% CI)	SDHR (95% CI)
Socio-demographics:			
Age at admission			
65-74	(ref)	(ref)	(ref)
75-84	1.08 (0.98, 1.18)	1.01 (0.87, 1.18)	1.13* (1.00, 1.27)
≥85	1.17** (1.04, 1.32)	1.06 (0.90, 1.24)	1.24** (1.06, 1.45)
Sex			
Male	(ref)	(ref)	(ref)
Female	1.06 (0.76, 1.49)	1.15 (0.76, 1.76)	0.99 (0.62, 1.59)
Race/ethnicity			
White, non-Hispanic	(ref)	(ref)	(ref)
Black, non-Hispanic	0.97 (0.85, 1.11)	1.11 (0.90, 1.38)	0.89 (0.76, 1.05)
Hispanic	0.97 (0.80, 1.18)	0.80 (0.57, 1.13)	1.06 (0.82, 1.36)
Other race/ethnicity	1.05 (0.78, 1.42)	1.43 (0.86, 2.38)	0.93 (0.64, 1.35)
Married	0.95 (0.84, 1.07)	0.96 (0.81, 1.13)	0.93 (0.79, 1.09)
Environment of Care Factors			
Fiscal year of admission			
2009-2011	(ref)	(ref)	(ref)
2012-2015	0.99 (0.90, 1.10)	1.15 (0.99, 1.34)	0.90 (0.81, 1.01)
Living arrangement before admission			
Acute hospital	(ref)	(ref)	(ref)
Home/assisted living	0.82*** (0.73, 0.91)	0.76** (0.64, 0.91)	0.91 (0.79, 1.04)
Nursing home	0.90 (0.76, 1.08)	0.75* (0.57, 0.99)	1.00 (0.82, 1.21)
Other	0.86 (0.67, 1.11)	0.85 (0.61, 1.18)	0.87 (0.63, 1.21)
Next of kin relationship to the Veteran			
Spouse	(ref)	(ref)	(ref)
Child	0.98 (0.86, 1.12)	1.04 (0.86, 1.26)	0.93 (0.78, 1.11)
Sibling	1.06 (0.91, 1.24)	1.29* (1.02, 1.63)	0.88 (0.71, 1.10)
Other relative	1.08 (0.88, 1.33)	1.20 (0.89, 1.62)	0.97 (0.72, 1.29)
Friend or other specified person of unknown relation	0.96 (0.75, 1.21)	0.94 (0.69, 1.27)	0.93 (0.71, 1.22)
Distance from next of kin ZIP code centroid to the CLC			
Quartile 1 ≤ 12.9 miles	(ref)	(ref)	(ref)
Quartile 2 (12.9-33.4) miles	0.98 (0.87, 1.10)	0.98 (0.83, 1.16)	0.97 (0.84, 1.13)
Quartile 3 (33.4-88.9] miles	0.95 (0.84, 1.07)	1.02 (0.85, 1.21)	0.90 (0.77, 1.05)
Quartile 4 >88.9 miles	0.90 (0.79, 1.01)	0.88 (0.75, 1.04)	0.90 (0.76, 1.06)
Facility Characteristics			
US Census region of the CLC			
Northeast	(ref)	(ref)	(ref)
Midwest	1.03 (0.81, 1.31)	1.09 (0.82, 1.45)	0.98 (0.76, 1.27)
South	1.28* (1.02, 1.61)	1.41* (1.05, 1.89)	1.18 (0.90, 1.55)
West	1.15 (0.86, 1.53)	1.39* (1.01, 1.92)	1.03 (0.75, 1.41)
Urban Influence Code for the CLC			
Large metro	(ref)	(ref)	(ref)
Small metro	1.00 (0.83, 1.21)	1.01 (0.76, 1.34)	1.02 (0.82, 1.27)
Micropolitan	1.04 (0.81, 1.34)	1.26 (0.89, 1.78)	0.94 (0.70, 1.26)
Noncore rural	0.91 (0.62, 1.35)	0.71 (0.50, 1.01)	0.98 (0.64, 1.52)
Complexity Level of the parent station			
1a (Highest)	(ref)	(ref)	(ref)
1b	1.00 (0.76, 1.31)	0.95 (0.68, 1.33)	1.04 (0.77, 1.40)
1c	1.13 (0.89, 1.42)	1.36 (0.94, 1.98)	0.97 (0.75, 1.26)
2	1.14 (0.89, 1.46)	1.05 (0.74, 1.48)	1.18 (0.87, 1.59)
3 (Least Complex)	1.12 (0.89, 1.40)	1.17 (0.85, 1.60)	1.06 (0.82, 1.37)
Bed Size of CLC			
<60 beds	(ref)	(ref)	(ref)
60-120 beds	0.92 (0.77, 1.10)	0.93 (0.73, 1.18)	0.91 (0.71, 1.15)
>120 beds	0.83 (0.69, 1.00)	0.89 (0.72, 1.11)	0.79 (0.61, 1.02)
Cardiovascular Risk Factors			
Number of qualifying conditions (CAD, stroke/TIA, and/or diabetes)			
1	(ref)	(ref)	(ref)
2	1.00 (0.91, 1.09)	1.03 (0.92, 1.16)	0.98 (0.86, 1.11)
3	0.95 (0.84, 1.07)	1.15 (0.93, 1.43)	0.85 (0.71, 1.01)
Congestive heart failure	0.90* (0.82, 0.99)	0.85* (0.75, 0.97)	0.92 (0.81, 1.04)
Hypertension	1.06 (0.87, 1.29)	1.15 (0.86, 1.53)	0.95 (0.76, 1.19)
Hyperlipidemia	0.95 (0.85, 1.05)	0.88 (0.75, 1.03)	1.00 (0.88, 1.13)
Venous thromboembolism	0.97 (0.85, 1.10)	0.96 (0.80, 1.14)	0.97 (0.82, 1.15)
Recent myocardial infarction (past year)	0.91 (0.80, 1.05)	0.98 (0.78, 1.23)	0.89 (0.74, 1.06)

Recent stroke/TIA (past year)	0.90 (0.81, 1.01)	0.89 (0.74, 1.07)	0.94 (0.81, 1.09)
Current smoker	1.06 (0.92, 1.23)	1.07 (0.84, 1.36)	1.05 (0.89, 1.25)
Body Mass Index			
Underweight (<18.5)	0.97 (0.83, 1.13)	0.90 (0.73, 1.11)	1.01 (0.84, 1.23)
Normal or healthy weight (18.5 to <25.0)	(ref)	(ref)	(ref)
Overweight (25.0 to <30.0)	0.89 (0.81, 0.98)	0.89 (0.77, 1.04)	0.89* (0.80, 0.996)
Obese (≥30)	0.77*** (0.67, 0.88)	0.72** (0.59, 0.87)	0.82* (0.69, 0.97)
Use of non-statin antilipemic medications	1.05 (0.91, 1.22)	0.97 (0.73, 1.27)	1.07 (0.90, 1.27)
Markers of Poor Prognosis			
Limited prognosis documented at admission	3.08*** (2.73, 3.48)	(N/A)	(N/A)
Advanced dementia	1.22** (1.09, 1.37)	1.25* (1.05, 1.48)	1.28** (1.10, 1.49)
Number of Elixhauser conditions			
0-1	(ref)	(ref)	(ref)
2-3	1.02 (0.88, 1.17)	0.93 (0.70, 1.23)	1.07 (0.88, 1.31)
4-5	1.04 (0.89, 1.22)	0.97 (0.73, 1.28)	1.10 (0.91, 1.34)
>5	1.09 (0.92, 1.29)	0.99 (0.74, 1.31)	1.18 (0.95, 1.47)
Recent weight loss	1.08* (1.00, 1.17)	1.06 (0.95, 1.18)	1.14* (1.02, 1.27)
Poor appetite	1.17** (1.07, 1.28)	1.10 (0.96, 1.27)	1.25*** (1.12, 1.40)
Renal failure	0.98 (0.88, 1.09)	1.02 (0.85, 1.22)	1.00 (0.87, 1.16)
Dehydration	1.80*** (1.34, 2.42)	1.23 (0.85, 1.79)	2.54*** (1.82, 3.55)
Acute change in mental status	1.15* (1.03, 1.28)	1.12 (0.96, 1.30)	1.13 (0.97, 1.31)
Shortness of breath	1.03 (0.94, 1.13)	1.00 (0.89, 1.12)	1.10 (0.97, 1.25)
Cancer	1.28*** (1.15, 1.42)	1.15 (0.99, 1.33)	1.42*** (1.25, 1.61)
Activities of Daily Living (ADL)			
Independent, requires supervision, or requires limited assistance	(ref)	(ref)	(ref)
Requires extensive assistance	1.06 (0.93, 1.21)	1.03 (0.85, 1.25)	1.09 (0.94, 1.26)
Dependent or totally dependent	1.28*** (1.14, 1.44)	1.22* (1.03, 1.44)	1.30** (1.11, 1.52)
Aggressive Behavior Symptoms			
None	(ref)	(ref)	(ref)
Moderate	1.08 (0.95, 1.23)	0.94 (0.75, 1.17)	1.19* (1.01, 1.39)
Severe	1.00 (0.81, 1.22)	0.96 (0.69, 1.33)	1.01 (0.78, 1.31)
Very severe	1.75*** (1.29, 2.37)	1.09 (0.63, 1.90)	2.05*** (1.53, 2.74)
Presence of any pain	1.07 (0.97, 1.19)	1.06 (0.89, 1.26)	1.06 (0.95, 1.19)
Infection	1.03 (0.94, 1.13)	0.91 (0.78, 1.06)	1.13* (1.02, 1.26)
Any swallowing difficulty or altered diet	1.10* (1.02, 1.18)	1.13 (0.99, 1.29)	1.07 (0.98, 1.18)
History of falls, hip fracture, and other fractures in past 180 days	0.96 (0.89, 1.04)	0.99 (0.89, 1.10)	0.93 (0.84, 1.04)
Total number of medication classes at admission			
<10	(ref)	(ref)	(ref)
10 to <15	1.08 (0.96, 1.22)	1.15 (0.98, 1.36)	1.04 (0.87, 1.23)
≥15	1.17* (1.03, 1.34)	1.23* (1.01, 1.49)	1.14 (0.95, 1.36)

*p<.05, **p<.01, ***p<.001

CLC=Community Living Center, CAD=coronary artery disease, TIA = transient ischemic attack

Table S-4. Sensitivity Analysis: Multivariable sub-distribution hazard ratios from Fine and Gray competing risk models assessing factors associated with statin discontinuation, overall and by whether patients had an end-of-life designation or hospice use at admission at admission, using alternative statin discontinuation variable requiring a 30-day gap in statin use. Associations which differed statistically from primary analyses are presented in bold, italicized, and underlined text.

	Full Sample (n=8,968)	End-of-Life Designation/Hospice (n=1,504)	No End-of-Life Designation/Hospice (n=7,464)
	SDHR (95% CI)	SDHR (95% CI)	SDHR (95% CI)
Socio-demographics:			
Age at admission			
65-74	(ref)	(ref)	(ref)
75-84	1.17* (1.02, 1.33)	1.09 (0.89, 1.34)	1.20* (1.03, 1.41)
≥85	1.24** (1.06, 1.46)	0.99 (0.79, 1.24)	1.38** (1.14, 1.68)
Sex			
Male	(ref)	(ref)	(ref)
Female	0.88 (0.53, 1.45)	1.03 (0.53, 2.00)	0.75 (0.37, 1.54)
Race/ethnicity			
White, non-Hispanic	(ref)	(ref)	(ref)
Black, non-Hispanic	0.98 (0.82, 1.18)	1.10 (0.85, 1.42)	0.92 (0.75, 1.12)
Hispanic	0.98 (0.78, 1.23)	0.92 (0.55, 1.54)	1.05 (0.76, 1.45)
Other race/ethnicity	1.08 (0.76, 1.53)	1.17 (0.57, 2.39)	1.10 (0.73, 1.64)
Married			
	0.88 (0.75, 1.02)	0.85 (0.66, 1.08)	0.88 (0.73, 1.07)
Environment of Care Factors			
Fiscal year of admission			
2009-2011	(ref)	(ref)	(ref)
2012-2015	0.99 (0.87, 1.11)	1.16 (0.97, 1.39)	0.90 (0.78, 1.05)
Living arrangement before admission			
Acute hospital	(ref)	(ref)	(ref)
Home/assisted living	0.89 (0.77, 1.02)	<u>0.83 (0.65, 1.05)</u>	0.99 (0.83, 1.19)
Nursing home	0.94 (0.78, 1.14)	<u>0.88 (0.63, 1.24)</u>	1.00 (0.80, 1.25)
Other	0.85 (0.62, 1.16)	<u>0.71 (0.42, 1.20)</u>	0.94 (0.66, 1.35)
Next of kin relationship to the Veteran			
Spouse	(ref)	(ref)	(ref)
Child	0.93 (0.77, 1.12)	0.97 (0.71, 1.31)	0.90 (0.71, 1.13)
Sibling	0.98 (0.80, 1.20)	<u>1.11 (0.81, 1.53)</u>	0.86 (0.65, 1.15)
Other relative	0.91 (0.71, 1.16)	1.08 (0.69, 1.67)	0.80 (0.58, 1.11)
Friend or other specified person of unknown relation	0.88 (0.68, 1.14)	0.81 (0.55, 1.18)	0.91 (0.67, 1.23)
Distance from next of kin ZIP code centroid to the CLC			
Quartile 1 ≤ 12.9 miles	(ref)	(ref)	(ref)
Quartile 2 (12.9-33.4) miles	0.97 (0.85, 1.11)	0.98 (0.79, 1.21)	0.95 (0.81, 1.12)
Quartile 3 (33.4-88.9] miles	0.96 (0.84, 1.09)	1.06 (0.83, 1.36)	0.86 (0.72, 1.04)
Quartile 4 >88.9 miles	0.88 (0.76, 1.02)	0.90 (0.71, 1.14)	0.86 (0.70, 1.05)
Facility Characteristics			
US Census region of the CLC			
Northeast	(ref)	(ref)	(ref)
Midwest	0.92 (0.71, 1.20)	0.83 (0.60, 1.15)	0.97 (0.71, 1.32)
<u>South</u>	1.13 (0.88, 1.45)	<u>1.10 (0.80, 1.52)</u>	1.16 (0.84, 1.60)
<u>West</u>	1.02 (0.76, 1.37)	<u>1.05 (0.76, 1.46)</u>	1.05 (0.74, 1.49)
Urban Influence Code for the CLC			
Large metro	(ref)	(ref)	(ref)
Small metro	1.14 (0.91, 1.41)	1.28 (0.94, 1.74)	1.06 (0.81, 1.39)
Micropolitan	1.07 (0.79, 1.44)	1.23 (0.83, 1.82)	0.98 (0.69, 1.38)
Noncore rural	1.07 (0.71, 1.61)	0.92 (0.63, 1.32)	1.09 (0.68, 1.77)
Complexity Level of the parent station			
1a (Highest)	(ref)	(ref)	(ref)
1b	1.09 (0.82, 1.44)	0.98 (0.70, 1.38)	1.16 (0.84, 1.60)
1c	1.05 (0.82, 1.36)	1.24 (0.84, 1.82)	0.97 (0.71, 1.32)
2	1.14 (0.86, 1.49)	1.23 (0.83, 1.83)	1.09 (0.77, 1.55)
3 (Least Complex)	0.98 (0.76, 1.26)	1.00 (0.73, 1.38)	0.98 (0.72, 1.33)
Bed Size of CLC			
<60 beds	(ref)	(ref)	(ref)
60-120 beds	1.00 (0.82, 1.24)	1.16 (0.87, 1.55)	0.91 (0.69, 1.20)
<u>>120 beds</u>	0.87 (0.69, 1.09)	1.03 (0.78, 1.38)	<u>0.75* (0.56, 0.995)</u>
Cardiovascular Risk Factors			
Number of qualifying conditions (CAD, stroke/TIA, and/or diabetes)			
One	(ref)	(ref)	(ref)
Two	0.98 (0.88, 1.10)	1.07 (0.92, 1.24)	0.95 (0.81, 1.12)
Three	0.88 (0.73, 1.05)	0.87 (0.63, 1.18)	0.87 (0.69, 1.09)
<u>Congestive heart failure</u>	0.94 (0.84, 1.04)	<u>0.92 (0.78, 1.09)</u>	0.93 (0.81, 1.06)
Hypertension	1.08 (0.86, 1.37)	1.19 (0.82, 1.72)	1.00 (0.76, 1.34)

<u>Hyperlipidemia</u>	0.92 (0.82, 1.03)	<u>0.81* (0.68, 0.97)</u>	0.99 (0.85, 1.16)
Venous thromboembolism	1.03 (0.88, 1.20)	1.01 (0.80, 1.26)	1.04 (0.87, 1.24)
Recent myocardial infarction (past year)	0.81 (0.65, 1.01)	0.90 (0.65, 1.25)	0.76 (0.58, 1.00)
Recent stroke/TIA (past year)	0.96 (0.84, 1.11)	1.04 (0.83, 1.31)	0.98 (0.82, 1.18)
Current smoker	1.06 (0.88, 1.27)	1.03 (0.79, 1.35)	1.05 (0.84, 1.31)
Body Mass Index			
Underweight (<18.5)	1.02 (0.84, 1.23)	1.01 (0.78, 1.32)	0.99 (0.74, 1.32)
Normal or healthy weight (18.5 to <25.0)	(ref)	(ref)	(ref)
Overweight (25.0 to <30.0)	<u>0.87* (0.78, 0.97)</u>	<u>0.80* (0.66, 0.97)</u>	0.92 (0.81, 1.06)
Obese (≥30)	<u>0.76** (0.63, 0.90)</u>	0.56*** (0.43, 0.74)	0.89 (0.72, 1.10)
<u>Use of non-statin anti-lipemic medications</u>	1.24* (1.02, 1.52)	<u>1.45* (1.02, 2.07)</u>	1.16 (0.93, 1.44)
<u>Markers of Poor Prognosis</u>			
Limited prognosis documented at admission	3.17*** (2.74, 3.66)	(N/A)	(N/A)
Advanced dementia	1.31*** (1.13, 1.51)	1.27 (1.01, 1.59)	1.41*** (1.17, 1.70)
Number of Elixhauser conditions			
0-1	(ref)	(ref)	(ref)
2-3	1.02 (0.83, 1.26)	0.88 (0.59, 1.32)	1.07 (0.82, 1.39)
4-5	1.06 (0.85, 1.31)	0.86 (0.59, 1.25)	1.18 (0.92, 1.52)
>5	1.08 (0.86, 1.35)	0.88 (0.59, 1.33)	1.20 (0.92, 1.56)
Recent weight loss	1.04 (0.94, 1.14)	0.94 (0.80, 1.10)	1.14* (1.00, 1.30)
<u>Poor appetite</u>	1.23*** (1.10, 1.37)	<u>1.18* (1.00, 1.38)</u>	1.31*** (1.14, 1.49)
Renal failure	0.94 (0.83, 1.06)	1.05 (0.85, 1.30)	0.95 (0.80, 1.14)
Dehydration	2.50*** (1.78, 3.51)	1.86 (1.05, 3.28)	2.86*** (1.90, 4.32)
<u>Acute change in mental status</u>	1.29** (1.11, 1.49)	<u>1.38** (1.09, 1.76)</u>	1.20 (0.97, 1.47)
Shortness of breath	1.08 (0.96, 1.22)	1.08 (0.93, 1.26)	1.14 (0.97, 1.36)
Cancer	1.23** (1.08, 1.40)	1.06 (0.86, 1.30)	1.40*** (1.20, 1.64)
Activities of Daily Living (ADL)			
Independent, requires supervision, or requires limited assistance	(ref)	(ref)	(ref)
Requires extensive assistance	1.01 (0.85, 1.19)	1.02 (0.78, 1.33)	1.06 (0.88, 1.27)
Dependent or totally dependent	1.26** (1.09, 1.45)	1.29* (1.04, 1.59)	1.25* (1.03, 1.52)
Aggressive Behavior Symptoms			
None	(ref)	(ref)	(ref)
<u>Moderate</u>	1.00 (0.85, 1.17)	<u>0.73* (0.53, 0.99)</u>	1.16 (0.97, 1.39)
Severe	0.93 (0.72, 1.19)	0.97 (0.64, 1.47)	0.91 (0.68, 1.21)
Very severe	1.70** (1.23, 2.37)	0.58 (0.24, 1.38)	2.11*** (1.53, 2.90)
Presence of any pain	1.07 (0.96, 1.20)	1.16 (0.95, 1.42)	1.02 (0.89, 1.16)
<u>Infection</u>	0.98 (0.87, 1.10)	<u>0.80* (0.65, 0.98)</u>	<u>1.11 (0.96, 1.28)</u>
Any swallowing difficulty or altered diet	1.03 (0.92, 1.14)	1.12 (0.91, 1.37)	0.97 (0.87, 1.09)
History of falls, hip fracture, and other fractures in past 180 days	0.93 (0.84, 1.02)	0.91 (0.77, 1.07)	0.93 (0.82, 1.06)
Total Number of Medication Classes at Admission			
<10	(ref)	(ref)	(ref)
10 to <15	0.99 (0.85, 1.16)	1.09 (0.88, 1.34)	0.94 (0.76, 1.16)
≥15	1.10 (0.93, 1.31)	1.16 (0.89, 1.51)	1.06 (0.84, 1.33)

*p<.05, **p<.01, p<.001

CLC=Community Living Center, CAD=coronary artery disease, TIA = transient ischemic attack

Summary of differences in hazard model results when using a 30-day vs. 14-day definition of statin discontinuation:

In residents without EOL designation/hospice, results were substantively unchanged, although a few associations became statistically not significant even though the magnitude of effect sizes were similar. However, some results changed substantively for residents with EOL designation/hospice. Of note, significant associations previously seen for admission from home/assisted living or nursing home, sibling next-of-kin, census region, and total number of medications at admission were attenuated and became non-significant. Several factors not significant in the main analysis became statistically significant: hyperlipidemia diagnosis (SDHR=0.81, 95% CI=0.68-0.97), being overweight (SDHR=0.80, 95% CI=0.66-0.97), use of non-statin anti-lipemics (SDHR=1.45, 95% CI=1.02, 2.07), poor appetite (SDHR=1.18, 95% CI=1.00-1.38), acute change in mental status (SDHR=1.38, 95% CI=1.09-1.76), moderate aggressive behavior (SDHR=0.72, 95% CI=0.53-0.99), and infection (SDHR=0.80, 95% CI=0.65-0.98).

Figure S-1. Construction of the sample of Veteran Community Living Center (CLC) stays for residents with limited life expectancy and/or advanced dementia (LLE/AD).




Figure S-2. Cumulative incidence of statin discontinuation, using primary statin discontinuation definition requiring a 14-day gap in statin use.




Figure S-3. Cumulative incidence of statin discontinuation, using alternative statin discontinuation definition requiring a 30-day gap in statin use.




Figure S-4. Cumulative incidence of statin discontinuation, using alternative statin discontinuation variable requiring a 30-day gap in statin use, stratified by end-of-life designation/hospice use at admission.

